Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1HP vs 3HP for TB Prevention in HIV-Uninfected Individuals
NCT04703075Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifapentine, isoniazid in Tuberculosis (TB), sponsored by Johns Hopkins University. Started Mar 2022; status: completed.
02
Drugs
rifapentineisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04703075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04703075.